Valuation: LONGEVEROPAR

Market Cap 21.68M 18.61M 17.47M 15.95M 30.1M 2.07B 30.25M 207M 80.1M 1.04B 81.4M 79.63M 3.46B P/E 2026 *
-0.94x
P/E 2027 * -1.45x
Enterprise Value 21.68M 18.61M 17.47M 15.95M 30.1M 2.07B 30.25M 207M 80.1M 1.04B 81.4M 79.63M 3.46B EV / Sales 2026 *
14.1x
EV / Sales 2027 * 3.32x
Free-Float
86.32%
Yield 2026 *
-
Yield 2027 * -
1 day+4.56%
1 week-12.70%
Current month+2.34%
1 month+17.53%
3 months-11.48%
6 months+23.78%
Current year+41.88%
1 week 0.65
Extreme 0.65
0.89
1 month 0.58
Extreme 0.5751
0.89
Current year 0.48
Extreme 0.475
1.23
1 year 0.48
Extreme 0.475
1.23
3 years 0.48
Extreme 0.475
35.6
5 years 0.48
Extreme 0.475
450
10 years 0.48
Extreme 0.475
450
Manager TitleAgeSince
Chief Executive Officer 65 2026-02-10
Chief Tech/Sci/R&D Officer 64 2014-10-08
Director of Finance/CFO 48 2026-08-16
Director TitleAgeSince
Chairman 64 2014-10-08
Director/Board Member 44 2020-02-29
Director/Board Member 75 2021-05-31
Date Insider Type Main position Quantity % Market Cap.
8/19/26 Free

Director

36,000 0.1194%
8/19/26 Free

Director

36,000 0.1194%
8/19/26 Free

Founder

286,000 0.9486%
Change 5-day change 1-year change 3-year change Capi.($)
+4.56%-12.70%-12.24%-96.88% 21.68M
-1.01%+1.48%+1.66%+23.62% 51.65B
+2.08%+0.73%+480.07%+570.24% 45.31B
+0.85%+4.90%+39.27%+17.90% 42.7B
-0.21%-0.41%+21.49%+85.71% 42.79B
-2.27%-3.02%+14.22%+51.50% 32.87B
+0.61%+1.75%+31.89%+136.55% 17.14B
-0.54%-3.19% - - 16.61B
-1.70%+3.06%+11.11%+28.57% 15.01B
-0.15%+2.23%+81.10%+49.16% 14.21B
Average +0.25%+1.31%+74.28%+96.26% 27.83B
Weighted average by Cap. -0.08%+2.74%+102.27%+140.03%

Financials

2026 *2027 *
Net sales 1.54M 1.32M 1.24M 1.13M 2.14M 147M 2.15M 14.67M 5.69M 74.06M 5.78M 5.65M 245M 6.53M 5.61M 5.26M 4.81M 9.07M 623M 9.11M 62.28M 24.14M 314M 24.53M 24M 1.04B
Net income -25.66M -22.02M -20.67M -18.88M -35.63M -2.45B -35.8M -245M -94.8M -1.23B -96.34M -94.25M -4.09B -25.54M -21.92M -20.57M -18.79M -35.46M -2.44B -35.63M -243M -94.36M -1.23B -95.89M -93.81M -4.07B
Net Debt - -
Logo LONGEVEROPAR
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Employees
38
Date Price Change Volume
26-08-26 US$0.7179 +5.57% 500,800
26-08-25 US$0.6800 -18.84% 1,592,148
26-08-24 US$0.8378 -0.84% 939,584
26-08-21 US$0.8449 +2.02% 770,448
26-08-20 US$0.8282 +0.72% 618,691
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.6800USD
Average target price
7.150USD
Spread / Average Target
+951.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LGVN Stock